Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%)...

|About: Sanofi (SNY)|By:, SA News Editor

Genzyme (GENZ +2.1%) is unexpectedly softening in its resistance to Sanofi-Aventis' (SNY +0.5%) courtship, apparently after being rebuffed in reaching out to other possible buyers including Pfizer (PFE), Johnson & Johnson (JNJ) and Merck (MRK). Currently under discussion: a CVR that would give Genzyme upside if leukemia drug Campath proves effective against MS.